Anke Kleine-Tebbe - Concepedia

Author

Anke Kleine-Tebbe

Also Known As

A Kleine-Tebbe, A Lorek, A. Kleine-Tebbe, A. Kleine‐Tebbe, Anke Kleine-Tebbe, Bernhard Heinrich, Christoph Kahl, Gabriele Kaltenecker

Publications

846

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin DRK Kliniken Berlin Kliniken Essen-Mitte Clinical Research Center for Hair and Skin Science St. Elisabeth-Hospital Bochum

About

Anke Kleine-Tebbe is an author at Charité - Universitätsmedizin Berlin specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	521
2	Health Sciences	4	4	121
3	Allergy	2	2	62
4	Allergy Medicine	2	2	62
5	Biochemistry	1	1	181

Anke Kleine-Tebbe

Publications

759

Citations

H-Index

Page 1

	Year	Citations
Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism Jan Budczies, Scarlet Brockmöller, Berit Müller, Journal of Proteomics Breast OncologyBiochemistryBeta-alanine MetabolismMedicineEstrogen Receptor	2013	181
Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes Gerhard Schäller, Ilka Fuchs, Thomas Gonsch, Journal of Clinical Oncology	2007	100
The prognostic significance of epithelial-mesenchymal transition in breast cancer. Ilka Fuchs, W. Lichtenegger, H. Buehler, PubMed	2003	75
Analysis of PIK3CA Mutations in Breast Cancer Subtypes Ruža Arsenić, Annika Lehmann, Jan Budczies, Applied immunohistochemistry & molecular morphology Breast OncologyCancer BiologyTumor BiologyExons 9Cancer Cell Biology	2013	61
Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy – A phase II-study Gero Wieners, Konrad Mohnike, Nils Peters, Radiotherapy and Oncology Breast OncologyRadiation TherapyMedicineBrachytherapyBreast Cancer	2011	56
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial M. Kaufmann, Nicolaì Maass, Serban Dan Costa, European Journal of Cancer Metastatic Breast CancerOncologyBreast OncologyMedicineMonica Trial	2010	38
Role of the Major Allergen (<i>Fel d</i> I) in Patients Sensitized to Cat Allergens Jörg Kleine‐Tebbe, Anke Kleine-Tebbe, S. Jeep, International Archives of Allergy and Immunology Hr ResponseAllergy MedicineImmunologyAllergenSkin Allergy	1993	37
Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™) Ilka Fuchs, Solveig Landt, Helmut Bueler, Breast Cancer Research and Treatment Cardiac MuscleHeart FailureMedicinePhysiologyHuman Myocardium	2003	37
Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study Varvara Kanti, Rima Nuwayhid, Judith Lindner, British Journal of Dermatology	2013	34
Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer Nadia Harbeck, Oleg Gluz, Matthias Christgen, Cancer Research Breast OncologyTrial AssumptionsPharmacotherapyEndocrine OncologyHer2+ Bc	2016	28

Page 1